Global Radiopharmaceuticals Market Research Report: Forecast (2025-2030)

Market Definition

Radiopharmaceuticals are specialized medications comprising a carrier molecule, often a pharmaceutical agent or biomolecule, combined with a radioactive isotope. These compounds emit radiation that can be detected by imaging devices for diagnostic purposes or deliver targeted radiation therapy to treat diseases, such as cancer.

Market Insights & Analysis: Global Radiopharmaceuticals Market (2025-30):

The Global Radiopharmaceuticals Market size was valued at around USD 7.11 billion in 2024 and is projected to reach USD 12.73 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 10.19% during the forecast period, i.e., 2025-30. With the increasing burden of the geriatric population, the incidence of multiple diseases, including cancer, cardiovascular diseases (CVDs), etc., is expected to increase enormously across the world. According to the American Society of Clinical Oncology (ASCO), most people who are diagnosed with cancer are older than 65. As a result, the adoption of radiopharmaceuticals for the diagnosis as well as the treatment of cancer, CVDs, and other diseases would increase, propelling the overall Radiopharmaceuticals Market. For instance, as per the World Health Organisation (WHO), it has been estimated that by 2030, the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. Further, the world’s population of people aged 60 years and older will reach around 2.1 billion by 2050.

*Boost strategic growth with in-depth market analysis - Get a free sample preview today!

Moreover, various awareness programs and initiatives are promoting early disease diagnosis and treatment across the world. These efforts by both government and non-government organizations encourage individuals to undergo regular health check-ups, including full-body screenings, to detect diseases like cancer at early stages when treatment is more effective.

Following that, the adoption of radiopharmaceuticals that have a crucial role to play in various diagnostic procedures, including imaging techniques, like positron emission tomography (PET) scans, which can detect abnormalities & diseases, such as cancer has witnessed a rise. Hence, with that, the Global Radiopharmaceuticals Market is presumed to flourish in the following years.

Global Radiopharmaceuticals Market Driver:

Increasing Prevalence of Chronic Diseases – There are a large number of patients with cardiovascular diseases globally due to factors, such as changing lifestyles, obesity, an aging population, improved survival rates from heart attacks and strokes, etc. For instance, the British Heart Foundation stated in 2024 that, around 620 million, which makes 1 in 13 people, are living with heart and circulatory diseases across the world.

With that, the adoption of radiopharmaceuticals to perform diagnosis and risk assessment and to monitor the influence of therapies on heart conditions is witnessing growth, propelling the overall Radiopharmaceuticals Market. Also, the prevalence of cancer is increasing across the globe and this is expected to drive the demand for radiopharmaceuticals

Global Radiopharmaceuticals Market Opportunity:

Enhancing Radiopharmaceuticals Efficiency with Artificial Intelligence (AI) – Worldwide, there is a shortage of radiologists, and those who are there are dealing with overwhelming workloads, often leading to burnout and compromising patient care. The shortage is expected to increase in the coming years. For instance, according to the Association of American Medical Colleges (AAMC), by 2033, there will be a shortage of up to 41,900 radiologists in the US. Hence, the utilization of AI-driven software in conjunction with radiopharmaceuticals tends to increase the efficiency and proficiency of overworked radiologists and would drive the radiopharmaceuticals market.

Also, along with the surge in the prevalence of cancer and other chronic diseases worldwide, the burden of the elderly population is increasing at an enormous rate. This would necessitate radiologists to utilize AI technology in combination with radiopharmaceuticals to get faster and more accurate results. Additionally, AI facilitates personalized treatment planning by leveraging vast amounts of patient data, thereby enhancing the treatment outcome, and increasing patient satisfaction.

Global Radiopharmaceuticals Market Challenge:

Supply Chain Challenges Associated with Radiopharmaceuticals - A robust pharmaceutical supply chain process guarantees that life-saving compounds are readily available at the right time and place. However, starting from production, synthesis, quality control, and dispensation to patients, the radiopharmaceutical supply chain process is highly complex. The short half-life of radiopharmaceutical products presents ongoing challenges for their upscale and widespread use, especially for therapeutic products.

Further, in 2023, Novartis halted new patient starts for Pluvicto, a radiopharmaceutical indicated for patients with metastatic castration-resistant prostate cancer (mCRPC) due to problems in the supply chain. Such supply chain problems can cause manufacturers to stop supplying their products temporarily. This can affect patient care and make doctors hesitant to offer these treatments. As a result, the value of the product and the radiopharmaceutical industry as a whole can decrease in the future.

Global Radiopharmaceuticals Market Trend:

Increasing Quest for New Radioisotopes & Radiopharmaceuticals – Driven by several limitations associated with the production of certain alpha-emitting isotopes, currently utilized in radiopharmaceuticals, the biopharma companies have begun to explore alternative radioisotopes, such as 211At, 223Radium, etc. For instance, in 2024, Novartis AG started a phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors. The newer radioisotopes tend to have intriguing opportunities for both imaging and therapy while potentially overcoming existing limitations. Further, coupled with an increase in cancer cases globally, the critical need to reduce the risks associated with conventional radiation therapy, has led to the exploration of newer radiopharmaceuticals. This, in turn, is expected to further drive the Global Radiopharmaceuticals Market during the forecasting years. 

Global Radiopharmaceuticals Market (2024-30): Segmentation Analysis

The Global Radiopharmaceuticals Market study by MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2024–2030 at the regional level. In accordance to the analysis, the market has been further classified as:

Based on the Indication

• Oncology
• Cardiology
• Gastroenterology
• Nephrology
• Others

The Oncology segment held a major share of the Global Radiopharmaceuticals Market. The growth has been attributed to the presence of a large number of individuals with different cancer types, such as prostate cancer, breast cancer, etc. For instance, as per the Global Cancer Observatory, in 2022, the estimated number of new cases of prostate cancer was around 1.47 million. Similarly, there were 2.30 million new cases of breast cancer diagnosed in 2022 across the globe. The demand for radiopharmaceuticals, thereby has increased considering the effectiveness of various radiopharmaceuticals in providing appropriate diagnosis and treatment of cancer.  

Further, driven by the growing demand for radiopharmaceuticals for cancer, the researchers are highly invested in developing novel radiopharmaceutical solutions to improve the lives of cancer patients. For instance, in 2023, researchers at Weill Cornell Medicine led a Phase I trial of a new drug that delivers potent radiation therapy directly and specifically to cancer cells in patients with advanced prostate cancer. The radiopharmaceutical has demonstrated promising antitumor activity.

Based on End User:

• Hospitals
• Medical Imaging Centres
• Others

Hospitals account for the largest share in the Global Radiopharmaceuticals Market. Hospitals are at the forefront of diagnosing and treating a wide range of conditions, including cancer, Alzheimer’s, etc., that benefit from radiopharmaceuticals. There has been significant progress in the development of hospitals globally, driven by increasing health awareness, and the aim to improve public healthcare.

Also, governments across different countries have been making efforts to continuously boost the healthcare infrastructure of their country, which has resulted in improved investments in new hospital construction. For instance, Hamdan Bin Rashid Cancer Hospital which is a 250-bed cancer facility is projected to open in 2026 in Dubai. Hence, as the number of hospitals increases in the coming years, it would generate an opportunistic demand for radiopharmaceuticals as well.

Global Radiopharmaceuticals Market (2024-30): Regional Projection

Geographically, the Global Radiopharmaceuticals Market expands across:

• North America
• South America
• Europe
• The Middle East & Rest of Africa
• Asia-Pacific

North America accounts for the largest share of the Global Radiopharmaceuticals Market. The dominance has been attributed to the presence of a large number of individuals with cancer in the region. For instance, as per the Global Cancer Observatory, about 2.67 million new cases of cancer were reported in 2022 in the North America region. The Global Cancer Observatory also mentioned that this number is expected to rise to 3.83 million by 2045. Thus, the large patient population pool has successfully accelerated the adoption of radiopharmaceuticals for the diagnosis as well as the treatment of disease.

Moreover, in coming years, with an increasing number of patients with cancer, the demand for radiopharmaceuticals for effective disease diagnosis and treatment would increase, escalating the North America Radiopharmaceuticals Market growth.

Global Radiopharmaceuticals Industry Recent Development:

• 2023: Curium Pharma announced that the European Commission has granted marketing authorization for PYLCLARI™, a radiopharmaceutical indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer.
• 2023: Eli Lilly and Company agreed to acquire the radiopharmaceutical firm POINT Biopharma Global for USD 1.4 billion.

Gain a Competitive Edge with Our Global Radiopharmaceuticals Market Report

• The Global Radiopharmaceuticals Market Report by Markntel Advisors provides a detailed & thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
• This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
• The Global Radiopharmaceuticals Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.